Serum Cholesterol Level Changes during Gonadotropin-Releasing Hormone-Agonist Therapy in Premenopausal Female Patients with Breast Cancer
- Author:
Sung Wook CHOI
1
;
Juhee KIM
;
Sa Ra LEE
;
Sung Hoon KIM
;
Hee Dong CHAE
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Menopausal Medicine 2024;30(2):120-125
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:To investigate the changes in cholesterol levels during medical ovarian suppression.
Methods:We reviewed the medical records and blood test results of 187 female patients with breast cancer who underwent gonadotropin-releasing hormone (GnRH)-agonist therapy for > 24 weeks at our hospital between 1 January 2018 and 31 December 2020.The study excluded patients in this cohort who had previously been diagnosed with dyslipidemia, diabetes, or had recently received lipid-lowering agents, resulting in a final sample size of 152 participants. The age at diagnosis and preoperative body mass index (BMI) were included as baseline demographics. A generalized additive mixed model was applied to analyze the relationship between the duration of GnRH-agonist treatment and changes in cholesterol levels.
Results:The study participants had a mean age of 42.5 ± 5.2 years and a mean preoperative BMI of 23.0 ± 3.6 kg/m2 ; the mean GnRHagonist therapy duration was 19.3 months (range: 5.6–37.7 months); and the total cholesterol level before GnRH-agonist treatment was 171 mg/dL that was significantly higher at 181 mg/dL (P = 0.03) during the most recent measurement. The total cholesterol level was unaffected by the GnRH-agonist therapy until 19.3 months after which it significantly increased by 1.28 mg/dL per month (P = 0.011).There was no significant effect of age, preoperative BMI, or the glomerular filtration rate on the total cholesterol levels.
Conclusions:Long-term GnRH agonist therapy for > 19 months can cause a significant increase in the serum cholesterol levels. To prevent complications, patients receiving the treatment should be informed and monitored for the possible progression of dyslipidemia.
